By Chris Farrell 25 Sep 2017
Meddevicetracker weekly round up
11 Total results for product and free and sample content found
By Tina Tan 18 Apr 2017
While the in vitro diagnostics landscape has seen players come and go, Roche Diagnostics has remained at the top. But the Swiss giant, like all its other smaller rivals, is facing a new reality, with increasing pressures to prove medical value, and a more stringent regulatory environment. Medtech Insight spoke to Roche Diagnostics' Jean-Claude Gottraux, head of centralized and point of care solutions, and Jean-Jacques Palombo, lifecycle leader for the company's cardiac, women's health and personalized health care solutions immunoassay portfolio, to gain their perspectives on how the sector has evolved and will continue to evolve. They also spoke about the company's strategy to address these changes and challenges.
By Sten Stovall 05 Apr 2017
Biogen's chief medical officer says iPhone technology should in future be used for early warning diagnosis of Alzheimer's Disease.
By Emily Hayes 05 Apr 2017
Interviews with US payers suggest that at first they are more likely to focus on promoting biosimilars in treatment-naïve patients, as opposed to switching those on branded drugs, according to a new Datamonitor report.
By Derrick Gingery 31 Mar 2017
Amendment defunding Planned Parenthood is one ACA repeal refugee that could hitch a ride with user fee bill, which would be 'problematic,' to say the least, for Democrats.
By Bowman Cox 17 Jan 2017
Congressional oversight agency urges FDA to make better use of foreign offices with more effective performance measures and staffing goals; GAO notes agency’s progress towards risk-based inspections – and its plan to revisit every site at least once every five years.
11 Oct 2016
Lilly’s solanezumab, Roche/Genentech’s Ocrevus and Cempra’s solithromycin are among the key therapies scheduled for major data read-outs or approval decisions in Q4 2016.
By Amanda Maxwell 10 Oct 2016
Medtech regulatory service providers cannot afford to "wait and see" on the final outcome of Brexit. Questions such as the appropriate base of operations to serve device companies looking to
By Jessica Merril 10 Oct 2016
Merck’s strong Phase II data testing Keytruda with chemotherapy
No Records Found
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: